Navigation Links
New way of viewing cells could lead to easier routes for drug manufacture
Date:12/10/2008

EAST LANSING, Mich. --- Research by a Michigan State University chemist could eventually lead to a quicker and easier way of developing protein-based drugs that are key to treating a number of diseases, including cancer, diabetes and hepatitis.

Proteins used in drug manufacture and research often are made within genetically modified Escherichia coli, a one-cell bacteria. That protein tends to collect into what scientists call inclusion bodies. Those hard-to-separate clumps render up to 95 percent of the protein unusable, according to associate chemistry professor David P. Weliky.

Some can be recovered by breaking down the protein to separate it, but because protein structure determines its function, another step must be added to "refold" it into its original configuration.

Weliky and colleagues took a closer look at the structure of the proteins that make up these inclusion bodies. Learning what makes them stick together might yield some clues as to how to separate them, he said, and that could make the manufacturing process more efficient.

Instead of employing more commonly used infrared spectroscopy to look at dehydrated samples, the researchers used nuclear magnetic resonance spectroscopy using whole cells. That technology analyzes the magnetic properties of an atom's nucleus.

While best known as medical diagnostic imaging technology, Weliky and colleagues view NMR as a powerful approach to analyzing biological molecules, including bacterial inclusion bodies. Because the inclusion body protein appeared to be predominantly folded rather than unfolded, it might be possible to extract protein without separating and then refolding, Weliky said.

"This study highlights our ability to probe the molecular structure of a single protein in whole cells and to apply advanced analytical and biochemical methods to a problem of general significance in biotechnology," Weliky said.


'/>"/>

Contact: Mark Fellows
mark.fellows@ur.msu.edu
517-884-0166
Michigan State University
Source:Eurekalert

Page: 1

Related biology news :

1. Forest Service launches Web-based forest threats viewing tool
2. ESF EURYI award winner aims to stop cancer cells reading their own DNA
3. Newly created cancer stem cells could aid breast cancer research
4. AIDS interferes with stem cells in the brain
5. Clemson scientists shed light on molecules in living cells
6. Social habits of cells may hold key to fighting diseases
7. UF scientists reveal how dietary restriction cleans cells
8. Human derived stem cells can repair rat hearts damaged by heart attack
9. Scientists identify embryonic stem cells by appearance alone
10. Cells united against cancer
11. Pittsburgh scientists identify human source of stem cells with potential to repair muscle
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... 16, 2014 Research and Markets ... the "Global Chemical Sensor Market 2015-2019" ... http://photos.prnewswire.com/prnh/20130307/600769 One major trend ... for medical sensors in biomedical applications. Chemical sensors ... and correct diagnosis during surgical procedures. The Global ...
(Date:12/11/2014)... , Dec. 10, 2014  That blood pressure plays a ... while. Hypertension – the medical term for high blood pressure ... 1800s, and the inflatable cuff that,s used in measuring blood ... mean there,s nothing new about hypertension, its triggers and its ... about the condition and the best ways to treat it. ...
(Date:12/10/2014)... 9, 2014 CIE San Diego has launched ... the connective tissue that enhances care coordination among social ... share client-level information; earned a second $1 million grant ... serving seniors aging in community and; will be recognized ... 11 th 4-6p. CIE San Diego ...
Breaking Biology News(10 mins):Global Chemical Sensor Market 2015-2019: Key Vendors are Abbott Laboratories, Bayer, Hoffmann La-Roche, Johnson & Johnson, NGK Spark Plugs and Robert Bosch 2Research points to need for new approaches to treatment of high blood pressure 2Research points to need for new approaches to treatment of high blood pressure 3Research points to need for new approaches to treatment of high blood pressure 4Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 2Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 3Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 4
... Atlantic salmon species will have its genome fully ... funding agencies and industry from Canada, Chile and ... Chilean Economic Development Agency, InnovaChile, Norwegian Research Council, ... form the International Cooperation to Sequence the Atlantic ...
... This release is available in German and ... Aconcagua Mountain in the Andes is polluted with PCBs. An ... carcinogenic chlorine compounds in samples taken from America,s highest mountain. ... are among the highest traces found anywhere in the world ...
... Norm for exhaust emissions went into force for all ... (TUM) have demonstrated an engine that is already close ... A research team headed by Prof. Georg Wachtmeister from ... reducing the pollutants in exhaust emissions to barely measurable ...
Cached Biology News:Genome BC collaborates with Chile and Norway to sequence salmon genome 2White, but not pure 2White, but not pure 3Munich lab demonstrates diesel truck engine with barely measurable emissions 2Munich lab demonstrates diesel truck engine with barely measurable emissions 3
(Date:12/15/2014)... Dec. 15, 2014  Ascendis Pharma A/S, a ... to address significant unmet medical needs, today announced ... 2 pediatric study to evaluate once-weekly TransCon Growth ... GHD.  This interim analysis consists of 25 patients, ... in the study, completing all six months of ...
(Date:12/13/2014)... (PRWEB) December 12, 2014 The ... million in 2013, and is expected to grow ... 2019. , Browse through the TOC of the ... industry trends and segments, with help of various ... The global DNA Microarray market consists of instrument, ...
(Date:12/13/2014)... 2014 QuickSTAT is making significant investments ... Chain capabilities, and is delighted to announce the opening ... serve Life Science clients in the region. , QuickSTAT ... warehouse, will provide 24/7 transportation and logistics services, as ... patient-clinical specimens, API, following IATA rules and EU GDP ...
(Date:12/13/2014)... ANTONIO , Dec. 12, 2014  Janssen Research ... data at the San Antonio Breast Cancer Symposium (SABCS) ... plus best supportive care (BSC) versus BSC when used ... receiving standard chemotherapy. This non-inferiority trial did not meet ... 15 percent or greater increase in the risk of ...
Breaking Biology Technology:Ascendis Pharma A/S Announces Positive Six-Month Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Six-Month Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Six-Month Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4DNA Microarray Market Is Expected to Grow at a CAGR of 15.2% from 2014 to 2019 - A Report by MicroMarket Monitor 2DNA Microarray Market Is Expected to Grow at a CAGR of 15.2% from 2014 to 2019 - A Report by MicroMarket Monitor 3DNA Microarray Market Is Expected to Grow at a CAGR of 15.2% from 2014 to 2019 - A Report by MicroMarket Monitor 4Quick Opens Office in France to Serve Life Science Community In France and Neighboring French-Speaking Countries 2Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 2Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 3Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 4Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 5Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 6Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 7Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 8Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 9Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 10Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 11Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 12
... 7, 2012 Innovative technology, local product advancements and ... business, Pioneer Hi-Bred, for continued growth, Pioneer President ... Sachs Agricultural Biotech Forum today. "Global trends ... developing economies are driving the demand for food and ...
... 7, 2012 Karyopharm Therapeutics Inc., a leader in ... presentations covering its Selective Inhibitors of Nuclear Export (SINE), ... on March 31 – April 4, 2012, in Chicago.  ... the use of Karyopharm,s novel SINE, along with Karyopharm ...
... N.J., March 6, 2012   Proteonomix, Inc. (OTC/BB: ... agreements with certain institutional investors, pursuant to which the ... E convertible preferred stock at an aggregate purchase price ... total of  895,291 shares of Proteonomix common stock) and ...
Cached Biology Technology:DuPont Leader Overviews 2012 Seed Research Pipeline with Investors 2DuPont Leader Overviews 2012 Seed Research Pipeline with Investors 3Karyopharm Therapeutics Announces Multiple Presentations on Selective Inhibitors of Nuclear Export (SINE) in Solid and Hematologic Malignancy Models and Spontaneous Canine Cancers at the American Association of Cancer Research (AACR) Meeting 2Karyopharm Therapeutics Announces Multiple Presentations on Selective Inhibitors of Nuclear Export (SINE) in Solid and Hematologic Malignancy Models and Spontaneous Canine Cancers at the American Association of Cancer Research (AACR) Meeting 3Proteonomix Announces a Private Placement of $3.8 Million 2Proteonomix Announces a Private Placement of $3.8 Million 3Proteonomix Announces a Private Placement of $3.8 Million 4